Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System

被引：21
|
作者：
Wang, Tiansheng [1 ]
Lu, Wenchao [2 ,3 ]
Tang, Huilin [4 ]
Buse, John B. [5 ]
Sturmer, Til [1 ]
Gower, Emily W. [1 ]
机构：
[1] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA
[2] Capital Med Univ, Beijing Shijitan Hosp, Peking Univ, Sch Clin Med 9, Beijing, Peoples R China
[3] Peking Univ, Sch Pharmaceut Sci, Dept Pharm Adm & Clin Pharm, Beijing, Peoples R China
[4] Peking Univ, Hlth Sci Ctr, Inst Drug Evaluat, Beijing, Peoples R China
[5] Univ N Carolina, Dept Med, Sch Med, Chapel Hill, NC 27515 USA
来源：
DIABETES CARE | 2019年 / 42卷 / 02期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.2337/dc18-1893
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：E21 / E23
页数：3
相关论文
共 50 条
  • [1] The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system
    Yang, Zheng
    Yu, Meng
    Mei, Mei
    Chen, Chongxin
    Lv, Yuhuan
    Xiang, Linyu
    Li, Rong
    [J]. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2022, 32 (02) : 504 - 510
  • [2] GLP-1RAs and risk of diabetic retinopathy: Analysis of the FDA Adverse Event Reporting System database
    Lu, Wenchao
    Tang, Huilin
    Shi, Luwen
    Wang, Tiansheng
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 449 - 449
  • [3] Food and Drug Administration Adverse Event Reports of Diabetic Retinopathy, Macular Edema and Blurred Vision Associated with GLP-1 Receptor Agonist Use
    Xiao, Grace
    Li, Albert
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [4] Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database
    Liu, Lulu
    Chen, Jia
    Wang, Lei
    Chen, Chen
    Chen, Li
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [5] The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
    Oezer, Kuebra
    Kolibabka, Matthias
    Gassenhuber, Johann
    Dietrich, Nadine
    Fleming, Thomas
    Schlotterer, Andrea
    Morcos, Michael
    Wohlfart, Paulus
    Hammes, Hans-Peter
    [J]. ACTA DIABETOLOGICA, 2023, 60 (11) : 1551 - 1565
  • [6] The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
    Kuebra Oezer
    Matthias Kolibabka
    Johann Gassenhuber
    Nadine Dietrich
    Thomas Fleming
    Andrea Schlotterer
    Michael Morcos
    Paulus Wohlfart
    Hans-Peter Hammes
    [J]. Acta Diabetologica, 2023, 60 : 1551 - 1565
  • [7] FDA approval of GLP-1 receptor agonist (liraglutide) for use in children
    Bacha, Fida
    [J]. LANCET CHILD & ADOLESCENT HEALTH, 2019, 3 (09): : 595 - 597
  • [8] Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database
    Zhou, Jianxing
    Zheng, You
    Xu, Baohua
    Long, Songjun
    Zhu, Li-e
    Liu, Yunhui
    Li, Chengliang
    Zhang, Yifan
    Liu, Maobai
    Wu, Xuemei
    [J]. BMC MEDICINE, 2024, 22 (01)
  • [9] Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database
    Jianxing Zhou
    You Zheng
    Baohua Xu
    Songjun Long
    Li-e Zhu
    Yunhui Liu
    Chengliang Li
    Yifan Zhang
    Maobai Liu
    Xuemei Wu
    [J]. BMC Medicine, 22
  • [10] The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy
    Varadhan, Lakshminarayanan
    Humphreys, Tracy
    Walker, Adrian B.
    Varughese, George I.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 103 (03) : E37 - E39
12345